Literature DB >> 9208933

Interactions of a bicyclic analog of colchicine with beta-tubulin isoforms alphabeta(II), alphabeta(III) and alphabeta(IV).

A Banerjee1, Y Engelborghs, A D'Hoore, T J Fitzgerald.   

Abstract

Tubulin exists as various isoforms, which differ in their assembly, drug-binding properties, and the dynamic properties of the microtubules they compose. One of the most striking differences in drug binding among the isoforms is observed with colchicine, which binds much better to the alphabeta(II) and alphabeta(IV) isoforms than to the alphabeta(III) isoform. Here we have studied the interaction of these isoforms with 2-methoxy-5-(2',3',4'-trimethoxyphenyl) tropone (MTPT), an analog of colchicine that lacks the B-ring. The kinetics of association and dissociation were studied fluorometrically, and the kinetic parameters for the two-step binding were determined for different beta-tubulin isoforms. The apparent on-rate constants for alphabeta(II), alphabeta(III) and alphabeta(IV) were 13358, 4558 and 10828 M(-1) s(-1), the off-rate constants (k(-2)) were 0.04, 0.03 and 0.02 s(-1), and the affinity constants are 3.33 x 10(5), 1.56 x 10(5) and 5.44 x 10(5) M(-1), respectively. The differences in kinetic parameters among different beta-tubulin isoforms are greatly reduced when the B-ring is removed. Our results indicate that the B-ring plays a major role in determining the isoform differences, and the results might be of importance for designing tissue-specific analogs of colchicine for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208933     DOI: 10.1111/j.1432-1033.1997.00420.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  Biphasic kinetics of the colchicine-tubulin interaction: role of amino acids surrounding the A ring of bound colchicine molecule.

Authors:  Suvroma Gupta; Mithu Banerjee; Asim Poddar; Asok Banerjee; Gautam Basu; Debjani Roy; Bhabatarak Bhattacharyya
Journal:  Biochemistry       Date:  2005-08-02       Impact factor: 3.162

2.  Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.

Authors:  Lee-Chuan C Yeh; Asok Banerjee; Veena Prasad; Jack A Tuszynski; Alexander L Weis; Tamas Bakos; I-Tien Yeh; Richard F Ludueña; John C Lee
Journal:  Invest New Drugs       Date:  2015-12-21       Impact factor: 3.850

3.  Nuclear βII-Tubulin and its Possible Utility in Cancer Diagnosis, Prognosis and Treatment.

Authors:  Richard F Ludueña; Consuelo Walss-Bass; Anna Portyanko; Jiayan Guo; I-Tien Yeh
Journal:  Front Cell Dev Biol       Date:  2022-05-30

4.  Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.

Authors:  Weiwei Wang; Hangxiao Zhang; Xumin Wang; Jordan Patterson; Philip Winter; Kathryn Graham; Sunita Ghosh; John C Lee; Christos D Katsetos; John R Mackey; Jack A Tuszynski; Gane Ka-Shu Wong; Richard F Ludueña
Journal:  Protoplasma       Date:  2016-12-09       Impact factor: 3.356

5.  beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion.

Authors:  A Portyanko; P Kovalev; J Gorgun; E Cherstvoy
Journal:  Virchows Arch       Date:  2009-04-10       Impact factor: 4.064

6.  Possible Roles of Specific Amino Acids in β-Tubulin Isotypes in the Growth and Maintenance of Neurons: Novel Insights From Cephalopod Mollusks.

Authors:  Richard F Ludueña
Journal:  Front Mol Neurosci       Date:  2022-04-14       Impact factor: 6.261

Review 7.  An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance.

Authors:  Amelia L Parker; Wee Siang Teo; Joshua A McCarroll; Maria Kavallaris
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

8.  β-tubulin carboxy-terminal tails exhibit isotype-specific effects on microtubule dynamics in human gene-edited cells.

Authors:  Amelia L Parker; Wee Siang Teo; Elvis Pandzic; Juan Jesus Vicente; Joshua A McCarroll; Linda Wordeman; Maria Kavallaris
Journal:  Life Sci Alliance       Date:  2018-04-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.